GH Research Announces Publication of Phase 2b Results for Mebufotenin in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026